Vipidia is a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
https://doi.org/10.21518/2079-701X-2015-2-66-69
Abstract
The global number of patients with diabetes mellitus (DM) has been growing steadily. Over the past decade, the number has more than doubled and reached 371 million people by 2013. [1] In most cases it is type 2 diabetes. The dangerous consequences of DM include micro- and macrovascular complications: nephropathy, retinopathy, lesions of the major blood vessels in the heart, brain and lower limbs. Late complications of DM are a major cause of disability and mortality of the patients.
About the Authors
T. B. Morgunova
Medical Faculty of the First Moscow State Medical University named after I.M. Sechenov
Russian Federation
Russian Federation
V. V. Fadeev
Medical Faculty of the First Moscow State Medical University named after I.M. Sechenov
Russian Federation
Russian Federation
References
1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 6-е изд. Сахарный диабет, 2013, 1.
2. Capuano A et al. Drug Des Devel Ther., 2013, 7: 989-1001.
3. Covington P et al. Clin Ther., 2008, 30: 499-512.
4. DeFronzo RA et al. Diabetes Care, 2008, 31: 2315-2317.
5. Pratley RE et al. Diabetes Obes Metab., 2009, 11: 167-176.
6. Nauck MA et al. Int J Clin Pract., 2009, 63: 46-55.
7. Pratley RE et al. Curr Med Res Opin., 2009, 25: 2361-2371.
8. Rosenstock J et al. Diabetes Obes Metab., 2009, 11: 1145-1152.
9. Del Prato S, Camisasca R, Wilson C, Fleck P. Diabetes Obes Metab., 2014, 16(12): 1239-46. doi: 10.1111/dom.12377. Epub 2014 Sep 25.
10. Hisada M et al. Abstract presented at the 48th Annual Meeting of the EASD 2012. Abstract 839-P.
11. FDA Guidance for Industry. Diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071 627.pdf [Accessed Jan 2014].
12. White WB, Cannon CP, Heller SR et al. N Engl J Med., 2013, 3, 369(14): 1327-35. doi: 10.1056/NEJMoa1305889. Epub 2013 Sep 2.
Review
For citations:
Morgunova TB, Fadeev VV. Vipidia is a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Meditsinskiy sovet = Medical Council. 2015;(2):66-69. (In Russ.) https://doi.org/10.21518/2079-701X-2015-2-66-69
Views:
502
Email this article 